Lo mejor de San Antonio Breast Cancer Symposium

MONALEESA-7 trial First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptorpositive, HER2-negative advanced breast cancer: Results from the randomized phase III

Nicolás Yáñez B.
Oncólogo Médico Hospital Regional Talca

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Dr. Felipe Carvajal Villarroel
Oncólogo Radioterapeuta
Instituto Nacional del Cáncer
Universidad de Chile

A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer

Mauricio Rivas
Residente Oncología Médica Pontificia Universidad Católica

EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Dr. Carlos Gallardo A.
Oncología Médica FALP

EAxillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Dr. Ariel Fariña
Radioterapia Oncológica
Fundación Arturo López Pérez

Comparación Randomizada De Tamoxifeno Y Supresión Ovárica Versus Tamoxifeno en Pacientes Premenopáusicas con Receptores Hormonales Positivos

Dra. Belén Hidalgo Fernández